Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
VRDN-002 by Viridian Therapeutics for Graves' Ophthalmopathy: Likelihood of Approval
VRDN-002 is under clinical development by Viridian Therapeutics and currently in Phase I for Graves' Ophthalmopathy. According to GlobalData, Phase...